364 related articles for article (PubMed ID: 34235004)
1. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Dong M; Wang HY; Zhao XX; Chen JN; Zhang YW; Huang Y; Xue L; Li HG; Du H; Wu XY; Shao CK
Hum Pathol; 2016 Jul; 53():25-34. PubMed ID: 26980034
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
6. Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.
Yee EJ; Gilbert D; Kaplan J; van Dyk L; Kim SS; Berg L; Clambey E; Wani S; McCarter MD; Stewart CL
J Surg Res; 2024 Apr; 296():742-750. PubMed ID: 38368775
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
[TBL] [Abstract][Full Text] [Related]
8. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1
Saito R; Abe H; Kunita A; Yamashita H; Seto Y; Fukayama M
Mod Pathol; 2017 Mar; 30(3):427-439. PubMed ID: 27934877
[TBL] [Abstract][Full Text] [Related]
9. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
[TBL] [Abstract][Full Text] [Related]
10. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.
Sun Q; Fu Y; Chen X; Li L; Wu H; Liu Y; Xu H; Zhou G; Fan X; Xia H
Gut Liver; 2022 Nov; 16(6):875-891. PubMed ID: 35611665
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological and molecular characteristics of Epstein-Barr virus associated gastric cancer: a single center large sample case investigation].
Yang Y; Liu YQ; Wang XH; Ji K; Li ZW; Bai J; Yang AR; Hu Y; Han HB; Li ZY; Bu ZD; Wu XJ; Zhang LH; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):451-458. PubMed ID: 31209416
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
15. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma.
Nakayama A; Abe H; Kunita A; Saito R; Kanda T; Yamashita H; Seto Y; Ishikawa S; Fukayama M
PLoS One; 2019; 14(1):e0211358. PubMed ID: 30695048
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-associated gastric cancer: A distinct subtype.
Yang J; Liu Z; Zeng B; Hu G; Gan R
Cancer Lett; 2020 Dec; 495():191-199. PubMed ID: 32979463
[TBL] [Abstract][Full Text] [Related]
17. Multi-layered control of PD-L1 expression in Epstein-Barr virus-associated gastric cancer.
Miliotis CN; Slack FJ
J Cancer Metastasis Treat; 2020; 6(13):. PubMed ID: 34212113
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
19. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients.
Yin YX; Ling YH; Wei XL; He CY; Wang BZ; Hu CF; Lin WP; Nie RC; Chen JW; Lin JL; Zhou J; Xie JJ; Yun JP; Xie D; Xue LY; Cai MY
Front Immunol; 2022; 13():973085. PubMed ID: 36591236
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Kawazoe A; Shitara K; Kuboki Y; Bando H; Kojima T; Yoshino T; Ohtsu A; Ochiai A; Togashi Y; Nishikawa H; Doi T; Kuwata T
Gastric Cancer; 2019 Jan; 22(1):69-76. PubMed ID: 29859006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
